CYP17 inhibitors for prostate cancer therapy.
**Title**: CYP17 inhibitors for prostate cancer therapy.

**Publication Type**: Journal Article

**Year of Publication**: 2011

**Authors**: Vasaitis, TS, Bruno, RD, Njar, VCO

**Journal**: J Steroid Biochem Mol Biol

**Volume**: 125

**Issue**: 1-2

**Pagination**: 23-31

**Date Published**: 2011 May

**ISSN**: 1879-1220

**Keywords**: Androgens, Clinical Trials as Topic, Disease Progression, Enzyme Inhibitors, Humans, Male

**Abstract**: Prostate cancer (PC) is now the second most prevalent cause of death in men in the USA and Europe. At present, the major... levels. Clearly, inhibition of the key enzyme which catalyzes the biosynthesis of androgens from pregnane precursors, 17\(^\alpha\)-hydroxy/17,20-lyase (hereafter referred to as CYP17) could prevent androgen production from all sources. Thus, total... (TOK-001) and TAK-700 in the clinic and in clinical development. Article from the special issue on Targeted Inhibitors.

**DOI**: 10.1016/j.jsbmb.2010.11.005


**PubMed ID**: 21092758

**PubMed Central ID**: PMC3047603

**Grant List**: R21 CA11799-01 / CA / NCI NIH HHS / United States
R21 CA117991-01 / CA / NCI NIH HHS / United States
R21 CA117991-02 / CA / NCI NIH HHS / United States
T32 AG000219 / AG / NIA NIH HHS / United States